Today, Pfizer and Biontech stated that their COVID-19 vaccine candidate was 95 percent effective at the end of its phase three clinical trial.
The two companies also declared that they've met a safety milestone required by the U.S. Food and Drug Administration to obtain emergency-use authorization.
Moderna reported a 94.5-percent efficacy rate on November 16.
According to Pfizer and Biontech, 3.8 percent of vaccine candidate recipients suffered fatigue and two percent experienced headaches.
Within a few days, Pfizer and Biontech plan to submit their data to government drug regulators around the world.
Pfizer and Biontech had a sample size of more than 43,000 research subjects.
Of those, 162 who took a placebo contracted COVID-19 compared to just eight who received the vaccine candidate.
Nine of those who took a placebo suffered a severe form of the disease whereas just one who took the vaccine candidate had severe COVID-19.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” Pfizer chairman and CEO Dr. Albert Bourla said in a news release. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
Pfizer and Biontech hope to be able to produce 50 million doses of their COVID-19 vaccine this year, followed by up to 1.3 billion doses in 2021.